

Bacterial Conjunctivitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/BDDFF6C94F64EN.html>

Date: June 2022

Pages: 31

Price: US\$ 2,000.00 (Single User License)

ID: BDDFF6C94F64EN

Abstracts

Bacterial Conjunctivitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bacterial Conjunctivitis – Drugs In Development, 2022, provides an overview of the Bacterial Conjunctivitis (Ophthalmology) pipeline landscape.

Bacterial conjunctivitis is an inflammation of the conjunctiva caused by pathogenic bacteria. Bacterial conjunctivitis is usually caused by *Staphylococcus aureus*, *Streptococcus pneumoniae*, *Haemophilus sp*, or, less commonly, *Chlamydia trachomatis*. Symptoms include redness in the white of the eye or inner eyelid, itchy eyes, blurred vision, increased sensitivity to light and burning eyes. Treatment includes antibiotics.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Bacterial Conjunctivitis – Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Bacterial Conjunctivitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bacterial Conjunctivitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Bacterial Conjunctivitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 2, 1, 2 and 1 respectively.

Bacterial Conjunctivitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Bacterial Conjunctivitis (Ophthalmology).

The pipeline guide reviews pipeline therapeutics for Bacterial Conjunctivitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Bacterial Conjunctivitis (Ophthalmology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Bacterial Conjunctivitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Bacterial Conjunctivitis (Ophthalmology)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Bacterial Conjunctivitis (Ophthalmology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Bacterial Conjunctivitis (Ophthalmology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and

understand from the know-how what drove them from pipeline.

Contents

Introduction

Global Markets Direct Report Coverage

Bacterial Conjunctivitis – Overview

Bacterial Conjunctivitis – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Bacterial Conjunctivitis – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Bacterial Conjunctivitis – Companies Involved in Therapeutics Development

Cellics Therapeutics Inc

IACTA Pharmaceuticals Inc

NTC srl

TaeJoon Pharmaceuticals Co Ltd

Takeda Pharmaceutical Co Ltd

TGV-Inhalonix Inc

Bacterial Conjunctivitis – Drug Profiles

CTI-005 – Drug Profile

Product Description

Mechanism Of Action

History of Events

CTO-0101 – Drug Profile

Product Description

Mechanism Of Action

History of Events

IC-702 – Drug Profile

Product Description

Mechanism Of Action

ketorolac tromethamine + levofloxacin – Drug Profile

Product Description

Mechanism Of Action

Mul-1867 – Drug Profile

Product Description

Mechanism Of Action

History of Events

SHP-640 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Bacterial Conjunctivitis – Dormant Projects

Bacterial Conjunctivitis – Product Development Milestones

Featured News & Press Releases

Jan 17, 2022: Lupin skids as failed USFDA specifications lead to recalls of 2 drugs

Nov 07, 2021: Lupin recalls Gatifloxacin in US market

Oct 03, 2013: Lupin launches Generic ZYMAXID Ophthalmic solution in the US

Aug 28, 2013: Lupin Receives FDA Approval For Gatifloxacin Eye Drops

Jul 01, 2013: Lupin Gets FDA Tentative Approval For Gatifloxacin Eye Drops

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Bacterial Conjunctivitis, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Bacterial Conjunctivitis – Pipeline by Cellics Therapeutics Inc, 2022
Bacterial Conjunctivitis – Pipeline by IACTA Pharmaceuticals Inc, 2022
Bacterial Conjunctivitis – Pipeline by NTC srl, 2022
Bacterial Conjunctivitis – Pipeline by TaeJoon Pharmaceuticals Co Ltd, 2022
Bacterial Conjunctivitis – Pipeline by Takeda Pharmaceutical Co Ltd, 2022
Bacterial Conjunctivitis – Pipeline by TGV-Inhalonix Inc, 2022
Bacterial Conjunctivitis – Dormant Projects, 2022
Bacterial Conjunctivitis – Dormant Projects, 2022 (Contd..1)

List Of Figures

LIST OF FIGURES

Number of Products under Development for Bacterial Conjunctivitis, 2022

Number of Products under Development by Companies, 2022

Number of Products by Targets, 2022

Number of Products by Stage and Targets, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

I would like to order

Product name: Bacterial Conjunctivitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/BDDFF6C94F64EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/BDDFF6C94F64EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

